NASD · Healthcare · Biotechnology · USA
Nurix Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Nurix Therapeutics is a clinical stage biopharmaceutical company developing targeted protein degradation medicines for cancer and inflammatory diseases. Its three investigational drug candidates include bexobrutideg, a BTK degrader; zelebrudomide, a dual BTK and transcription factor degrader; and NX-1607, a CBL-B inhibitor.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Nurix Therapeutics Inc stock.
Undervalued: intrinsic value $62.88 per share, market price $26.10, margin of safety 58.5% (as of 2026-10-20).
Discounting its cash flows at 12.7% (average of 3 methods) values the shares at $62.88; the price of $26.10 is 58% below that value, and 67% of that value comes from beyond year five.
Leak Score: 74/100 on 9 of 12 signals (Clear Leak).
17 more funds hold it; the full list is part of the paid plan.
3 more in this industry show a wider margin of safety.
NRIX is undervalued (as of the 2026-10-20 close). Discounting its cash flows at 12.7% (average of 3 methods) values the shares at $62.88; the price of $26.10 is 58% below that value, and 67% of that value comes from beyond year five.
$62.88 per share (as of the 2026-10-20 close), against a market price of $26.10. That is a margin of safety of 58.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
74 out of 100, which we rate "Clear Leak", on 9 of 12 value investing signals.